Blood Pressure Targets

For decades, the standard blood pressure target was <140/90 mmHg for most adults, a threshold derived from observational epidemiological data showing a continuous relationship between blood pressure and cardiovascular risk. The HOT trial (1998) randomized 18,790 hypertensive patients to diastolic BP targets of ≤90, ≤85, or ≤80 mmHg and found minimal benefit from lower targets in the overall population, though diabetic patients showed improved outcomes with lower targets. The question of whether more aggressive lowering would further reduce cardiovascular events remained contentious, setting the stage for one of the most debated topics in primary care medicine.

The ACCORD-BP trial (2010) in type 2 diabetic patients randomized to systolic <120 vs <140 mmHg found no significant reduction in the primary composite cardiovascular endpoint with intensive control, though stroke was reduced. This result dampened enthusiasm for intensive targets and reinforced the 140/90 threshold. Then SPRINT (2015) dramatically reignited the debate: among 9361 high-risk non-diabetic patients, targeting systolic <120 vs <140 mmHg reduced major cardiovascular events by 25% and all-cause mortality by 27%. SPRINT was stopped early for benefit. The contrast between ACCORD-BP (negative) and SPRINT (positive) generated intense debate about whether the difference reflected diabetes-specific biology or methodological factors.

Post-SPRINT, the STEP trial (2021) from China confirmed intensive targets in a large elderly population: targeting systolic 110-130 vs 130-150 mmHg in 8511 patients aged 60-80 reduced major cardiovascular events by 26%. The ESPRIT trial extended findings to acute stroke patients. Meta-analyses incorporating SPRINT, STEP, and other trials consistently showed that lower BP targets reduce cardiovascular events across most populations, though the absolute benefit varies with baseline risk. However, concerns about SPRINT's use of unattended automated measurement (which yields readings 5-10 mmHg lower than standard office measurement) complicated translation to clinical practice, where most BP is measured conventionally. The true target in standard office measurement terms may be closer to 130-135 mmHg.

The 2017 ACC/AHA guidelines were the first to adopt a <130/80 mmHg target for most adults, based heavily on SPRINT. This represented a significant departure from JNC 8 (2014), which had relaxed targets to <150/90 for patients over 60. The ESC/ESH 2018 guidelines took a more conservative approach, recommending <140/90 initially and then 120-130 systolic if tolerated. This transatlantic disagreement highlighted the challenge of translating SPRINT's automated measurements to real-world practice. The 2023 ESH guidelines moved closer to <130/80 for most patients. The net result is a global trend toward lower targets, with growing consensus around <130/80 as the goal for most adults at moderate-to-high cardiovascular risk.

The field is moving toward individualized blood pressure targets based on absolute cardiovascular risk, age, frailty, and comorbidities. While <130/80 is appropriate for most moderate-to-high-risk adults, more lenient targets (140-150) may be appropriate for frail elderly patients, those with orthostatic hypotension, or patients experiencing medication side effects. The measurement method matters enormously: the gap between automated unattended measurement (SPRINT-style) and routine office measurement means that a SPRINT target of <120 may correspond to <130-135 in standard practice. Home blood pressure monitoring and ambulatory BP monitoring are increasingly recommended for treatment guidance. The debate continues about the optimal target for patients with diabetes, CKD, and those over 80.